Skip to content
Home/Companies/Biotech/Stragen
Stragen

Stragen

Biotech·Switzerland·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Stragen?

Stragen is a Swiss Biotech company, currently owned by ARCHIMED since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
ARCHIMED
Investor
ARCHIMED
MED III · 2021 · Buyout

Key facts

HQSwitzerland
SectorBiotech
Websitewww.stragen.com

More from MED III

Other portfolio companies in the same fund.

BioVendor Group
Active
MedTechCzech Republic· 2025
DermaPharm
DermaPharm
Active
HealthTechDenmark· 2025
Natus Sensory
Natus Sensory
Active
MedTechUS· 2022
PlasmidFactory
PlasmidFactory
Active
BiotechGermany· 2022
Title21 Health Solutions
Title21 Health Solutions
Active
HealthTechUS· 2022
Aliri
Aliri
Active
PharmaUS· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Stragen?

Stragen is currently owned by ARCHIMED, through MED III, since 2021.

When did ARCHIMED acquire Stragen?

ARCHIMED acquired Stragen in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue